Adalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar program from Enzene. Adalvo today announced the acquisition of a romiplostim biosimilar program referencing Nplate(R) from Enzene, strengthening its biosimilars portfolio and accelerating the company's expansion into complex biological medicines. The transaction builds on Adalvo's established capabilities in bringing complex pharmaceutical products to global markets and extends these capabilities into biologics. Beyond romiplostim, Adalvo is actively building a broader portfolio of biosimilar assets across the full value chain, from cell line development through to commercialization. For Adalvo's global network of partners, this means access to a broader portfolio of technically complex medicines through the same integrated development, regulatory, supply and commercial platform. For Adalvo, it creates an additional engine for long-term growth in a strategically important segment of the pharmaceutical market. The acquired program references Nplate(R)(romiplostim), a treatment indicated for adult and chronic pediatric immune thrombocytopenia (ITP). Developed using microbial cell line technology, the program represents a technically sophisticated biosimilar opportunity aligned with Adalvo's focus on high-value, complex medicines. With the reference product generating approximately USD 1.5 billion in global sales in 2025, the program represents a significant global opportunity and supports Adalvo's ambition to broaden access to high-quality biological medicines across international markets. Biosimilars are a natural extension of Adalvo's capabilities into complex biological medicines and an important part of its long-term growth strategy. This acquisition strengthens its portfolio with a technically sophisticated program while bringing together Enzene's scientific and manufacturing expertise with Adalvo's global development, regulatory and commercial platform. News Medical is proud to partner with Enzene, a highly respected organization with deep scientific and manufacturing expertise, and News Medical look forward to establishing a long-term strategic relationship that extends beyond a single program." Anil Okay, CEO, Adalvo Limited "This partnership with Adalvo is a milestone for Enzene. Having taken romiplostim from cell line development through to regulatory approval and commercial supply in India, we are entrusting a strong global partner to bring it to patients internationally, while Enzene continues as development and manufacturing partner. This transaction strengthens Enzene's position as a leading global biosimilar CDMO, developing, scaling and manufacturing complex biologics for partners worldwide. Enzene is built on deep scientific, regulatory and GMP expertise and a proven multi-market track record. We look forward to building on this relationship with Adalvo in the years ahead," Himanshu Gadgil, Ph.D. CEO, Enzene For Enzene, the transaction marks a strategic inflection point. Having built an integrated biosimilar platform spanning cell line development, process development, clinical supply and commercial manufacturing, Enzene is now a global biosimilar CDMO of choice, focusing its business model fully on contract development and manufacturing services for biologics. Enzene will continue to serve as development and manufacturing partner to Adalvo for the romiplostim program, including support for regulatory filings with the US FDA, the European Medicines Agency and other international regulatory authorities, and will supply the product from its GMP-approved facilities in Pune, India. The partnership with Adalvo marks a significant step in Enzene's transition of its biosimilar pipeline to commercial partners, while expanding its CDMO offering to global biopharmaceutical companies. This acquisition reflects Adalvo's continued commitment to building a differentiated portfolio of high-value pharmaceutical products through strategic investments, licensing opportunities and targeted acquisitions. By expanding the biosimilars market, Adalvo takes another significant step in its evolution as a global pharmaceutical company dedicated to delivering complex and innovative treatment solutions across international markets. Be the first to rate this article

Enzene, a global biomanufacturing organisation, has launched NeX™, an end-to-end partnership model enabling governments, institutions, and biopharma companies to establish local biomanufacturing capabilities. Built on Enzene's EnzeneX® fully-connected continuous manufacturing platform, NeX offers facility design support, technology transfer, workforce training through its SparX™ curriculum, and ongoing operational assistance. The programme aims to make biologics manufacturing more accessible and affordable. According to Enzene CEO Himanshu Gadgil, conventional biologics plants cost $300–$400 million to build, whilst the company's continuous manufacturing platform achieves equivalent output for $60–$80 million. Facilities built under the programme can reach commercial readiness in under three years. Enzene is currently in discussions with multiple governments and corporations globally. Participating organisations may also access products from Enzene's biosimilar portfolio for regional manufacture.